Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: May 14, 2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million
Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025
Read more at globenewswire.com6.74
-0.04 (-0.59%)
NASDAQ:FBIO (6/16/2025, 8:00:02 PM)
1.84
-0.01 (-0.54%)
Find more stocks in the Stock Screener
